top of page
Farcast Bio - Banner - Website - TiME.png


With Biosignatures For Precision Guidance 

Developing new cancer therapies is risky and expensive. Root causes include reliance on over-simplistic models in translational oncology research that do not capture full human complexity, as well as the lack of functional biosignatures that can be used through out clinical development to correlate individual, multimodal tumor data with historical insights utilizing modern Artificial Intelligence (AI) capabilities  

With our experience of processing nearly 24,000 live human tumors over a decade, we help our clients manage and reduce this risk. The Farcast platform has a proven ability to collect multiple horizontal data in terms of multi-cell type (tumor, stromal, immue) and tumor types, as well as vertical data in terms of multi-data types (not just genomic) and population types for a variety of therapy mechanisms across a range of cancers. These data are multiplexed and analyzed by proprietary AI algorithms in the platform to create biosignatures for predicting tumor response to novel therapies and their combinations

Studying the true human tumor and immune response to a novel agent using a wide range of assays that include Histopathology, IHC, Gene Expression signatures, Cytokine profiling, Flowcytometry and Spatial Biology assays and applying AI to create biosignatures from such tumor biology big data can help guide the therapy through clinical development with more odds of success than traditional methods

Test Combination Therapies

Develop combination strategy and test synergy with existing treatments

Evaluate Mechanism of Action

Gain confidence in the mechanism of your therapeutic candidate 

Discover Predictive Biosignatures

Optimal patient stratification for enhanced response rates 

Scout New Indications

Expand the range of indications of your pipeline

Anchor 1
bottom of page